Please wait a minute...
TMR Modern Herbal Medicine  2018, Vol. 1 Issue (4): 203-208    DOI: 10.12032/TMRmhm2017A27
Original Article     
Clinical observation of Furongtongmai capsule on the lower extremity Atherosclerotic Occlusive Disease after Intervention Operation
Yao Wei1,*(), Su Xiu-Hai1, Wang Yuan-Song1, Du Yan-Ling1, Gao Zhan-Yi1, Gao Yin-Sheng1, Li Na1, Feng Na-Na1, Chen Qing1, Guo Hua1
1 Cangzhou Hospital of Integrated TCM-WM Hebei, Cangzhou, Hebei, China.
Download: HTML     PDF(379KB)
Export: BibTeX | EndNote (RIS)      

Objective: To investigate the effect of Furongtongmai capsule on the in-stent restenosis (ISR) of superficial femoral artery after interventional operation in lower extremity Arteriosclerosis Occlusion (ASO). Methods: A total of 110 inpatients with ASO who performed Superficial femoral artery stent implantation were randomly divided into observation group and control group, with 55 cases in each group.Both groups received Aspirin 100 mg/d and Clopidogrel 75 mg/d. The observation group was given Furongtongmai capsule on the basis of routine treatment. After continuous treatment for 6 months, the clinical efficacy, Ankle Brachial Index (ABI), high-sensitivity C-reactive protein (Hs-CPR) and ISR were compared between the two groups. Results: At 6 months after operation, the plasma levels of Hs-CRP in the two groups were significantly lower than those in the control group (P < 0.05). The ABI of treatment group was significantly higher than the control group (P < 0.05). There was a statistically significant difference in ISR incidence between the treatment group and the control group 6 months after surgery (9.09% vs 27.78%, P < 0.05). Conclusion: Furongtongmai Capsule can inhibit Hs-CRP in patients with ASO after femoral artery intervention, improve the ankle brachial index and reduce the incidence of ISR.

Highlights

The restenosis rate in patients with lower extremity Arteriosclerosis Obliterans was higher after the bare stent implantation, and the effect of double resistance was not good. In this paper, the effect of Furongtongmai capsule on restenosis after stent implantation was observed by clinical trial. Furongtong mai capsule can reduce the restenosis rate in patients after operation by multiple targets, such as reducing the vascular inflammation, raising ABI and increasing the blood flow of the lower limbs. it is on the threshold of the application of Chinese medicine for Arteriosclerosis Obliterans of lower extremities.



Key wordsFurongtongmai capsule      Lower extremity atherosclerotic occlusive disease      intervention operation      restenosis rate      Hs-CRP     
Published: 06 September 2018
Fund:  This work was partly supported by Hebei administration of traditional Chinese medicine (2014123)
Corresponding Authors: Yao Wei     E-mail: 13613271693@163.com
Cite this article:

Yao Wei, Su Xiu-Hai, Wang Yuan-Song, Du Yan-Ling, Gao Zhan-Yi, Gao Yin-Sheng, Li Na, Feng Na-Na, Chen Qing, Guo Hua. Clinical observation of Furongtongmai capsule on the lower extremity Atherosclerotic Occlusive Disease after Intervention Operation. TMR Modern Herbal Medicine, 2018, 1(4): 203-208. doi: 10.12032/TMRmhm2017A27

URL:

https://www.tmrjournals.com/mhm/EN/10.12032/TMRmhm2017A27     OR     https://www.tmrjournals.com/mhm/EN/Y2018/V1/I4/203

project Control group Observation Group P
Age 52.8 ± 5.3 50.8 ± 6.0 0.858
Female 16(29) 18(32.7) 0.680
Diabetes 25(45.4) 27(49) 0.702
Hypertension 42(76.4) 39(65.4) 0.516
High cholesterol 38(69) 41(74.5) 0.525
Coronary heart disease 16(29.1) 13(23.6) 0.516
Lesion length 103.6 ± 24.5 113.2 ± 19.0 0.747
Table 1 Comparison of basic data between the two groups
cases Preoperative 6 months after surgery t P
Hs-CRP mg.L-1 observation 55 9.50 ± 1.29 3.13 ± 0.40 -10.330 0.000
contral 54 8.25 ± 0.96 7.20 ± 0.68
ABI observation 55 0.59 ± 0.10 0.94 ± 0.06 6.670 0.001
contral 54 0.55 ± 0.08 0.64 ± 0.06
Table 2 Comparison of No, Hs-CRP and ABI between the two groups
observation(55) contral(54) t P
Restenosis rate 9.09 %(5) 27.78 %(16) 7.39 0.007
Table 3 Comparison of two groups of restenosis
1.   Laird JR, Katzen BT, Scheinert D,et a1. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal pepliteal artery:twelve-month results from the RESILIENT randomized trial. CircCardiovasc Interv 2010, 11: 267-276.2. Lv SQ, Zhang SF, Wang M.Effect of furongtongmai capsule on serum lipid metabolism and endothelial cell iNOS in diabetic rats. World Latest Med Inf 2015, 3: 15-16.3. Department of vascular surgery, Chinese medical association. Guidelines for the treatment of arteriosclerotic occlusion of lower extremities. Chin J Pract Surg 2008, 28: 923-924.4. Liu M, Zhao YL.Correlation between TASC II Typing and TCM Syndrome Typing in Patients with Arteriosclerosis Ob-literans. Chin J Surg Integr Trad Western Med 2012, 24: 433-435.5. Tendera M, Aboyans V, Bartelink ML,et a1. ESCGuidelinesonthe diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011, 32: 2851-2906.6. Dake MD, Ansel GM, Jaff MR,et a1. Paclitaxel- eluting stents showsuperiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve- month Zilver PTX randomized studyresults. Circ Cardiovasc Interv 2011, 4: 495-504.7. Dake MD, Ansel GM, Jaff MR,et a1. Sustained safety and effectiveness of paclitaxel- eluting stents for femoropopliteal lesions: 2- year follow- up from the Zilver PTX randomized and single- arm clinical studies. J Am Coll Cardiol 2013, 61: 2417-2427.8. Li HB, Jiang ZA, Liu XD,et a1. Factors influencing restenosis in 89 elderly patients with coronary heart disease after PCI. Chin J Gerontol 2015, 35: 5156-51579. Zhang GS.A review on treating CHD restenosis in TCM. Clin J Chin Med 2016, 8: 145-146.10. Ye DH, Chen L.Clinical study on treatment of restenosis after interventional treatment of arteriosclerosis obliteration of lower extremity by tougu tongmai decoction. Chin Arch Trad Chin Med 2016, 6: 1401-1404.11. Lv SQ, Zhang SF,Su XH.Clinical Observation on the Treating Diabetic Peripheral Vascular Lesions by Furong Tongmai Capsule Combined with TCM Leg Bath. World Chin Med 2016, 11: 1474-147612. Welt FG, Rogers C.Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002, 22: 1769-1776.13. Wang M, Su XH,et a1. Clinical observation of 60 cases of diabetic lower limb angiopathy treated by furongtongmai capsule and alprostadil injection. Heibei J Trad Chin Med 2014, 1: 60-62.14. Yu WX, Tian FS, Su XH.Furongtongmai capsule improves the blood flow in lower extremities of diabetic peripheral vascular disease. Mod Med J China 2007, 2: 69-71.15. Guo HY, Gao SH, Lan SH Treating 58 cases of diabetic foot syndrome differentiation with furongtongmai capsule. Guangming J Chin Med 2010, 5: 886-887.
No related articles found!